200002-41-1Relevant articles and documents
Regio- and Stereoselective Ring-Opening Metathesis Polymerization of Enantiomerically Pure Vince Lactam
Benedikter, Mathis J.,Frater, Georg,Buchmeiser, Michael R.
, p. 2276 - 2282 (2018)
The ring-opening metathesis polymerization (ROMP) of (+)-Vince lactam [(S)-azabicyclo[2.2.1]hept-5-en-3-one] (1) and its N-benzyl, N-trimethylsilyl (TMS), and N-tert-butoxycarbonyl (Boc) derivatives (2a-c) is reported. Highly cis-syndiotactic (st) poly(Vince lactam) was readily accessible by using the cyclometalated ruthenium complex Ru[CH(2-OiPr-Ph)](Piv)(1-mesityl-3-C4H8-imidazol-2-ylidene) (Piv =2,2-dimethylpropanoate) (4); however, small amounts of trans double bonds (ca. 5%) formed. Highly cis-st (>98%) polymers were accessible by the action of the monoaryloxide pyrrolide (MAP) type complexes W(N-2,6-iPr2C6H3)(CHCMe2Ph)(Pyr)(HMTO) (Pyr = pyrrolide, HMTO = 2,6-(2,4,6-Me3C6H2)2C6H3O) (7) and W(O)(CHCMe2Ph)(PMe2Ph)(Me2Pyr)(TPPO) (TPPO = 2,3,5,6-tetraphenylphenolate) (8). Complementary, cis-isotactic (>98% cis-it) polymers were prepared by the action of Mo(N-2,6-Me2C6H3)(CHCMe2Ph)(OBiphen) (OBiphen = 3,3′-di-tert-butyl-5,5′,6,6′-tetramethyl-1,1′-biphenyl-2,2′-diolate) (5) and its tungsten analogue W(N-2,6-Me2C6H3)(CHCMe2Ph)(OBiphen) (6). Notably, none of these Mo- and W-based initiators polymerize unprotected Vince lactam. Deprotection of poly(N-TMS Vince lactam) and poly(N-Boc Vince lactam) with neat trifluoroacetic acid allowed for the isolation of all-cis highly tactic poly(Vince lactam).
3-CARBON SUBSTITUTED 4-AMINOCYCLOPENT-1-ENE-1-CARBOXYLIC ACID COMPOUNDS AS INHIBITORS OF GAMMA-AMINOBUTYRIC ACID (GABA) AMINOTRANSFERASE
-
Paragraph 0102; 0106, (2019/10/29)
Disclosed are cyclopentene compounds for use as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase (AT) and/or ornithine aminotransferase (OAT). The disclosed cyclopentene compounds include 3-carbon substituted 4-aminocyclopent-1-ene-carboxylic acid compounds which may be formulated in pharmaceutical composition for treating diseases and disorders associated with GABA-AT and/or OAT activity, including epilepsy, addiction, and hepatocellular carcinoma (HCC).
SPIRO [2.4]HEPTANES FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS
-
, (2013/08/28)
Compounds, methods, and compositions for the treatment of infections in or exposure to humans and other host animals of Flaviviridae viruses, including HCV, that includes the administration of an effective amount of a spiro[2.4]heptane as described herein